Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed a Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission (" SEC ") to register Relief as a rep...
GENEVA, SWITZERLAND / ACCESSWIRE / December 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQBRLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent compa...
NRx Pharmaceuticals (NASDAQ:NRXP) provides a new safety update on Zyesami (aviptadil), which is being tested in the ACTIV-3b Critical Care Phase 3 study. Shares up 3.3% premarket at $5.95. In its third scheduled analysis, the study’s Independent Data Safety Monitoring Board found ...
Relief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16th Relief invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR Newswire ...
Relief Therapeutics Holding (OTCQB:RLFTF) announces that the parent company of its partner, NRx Pharmaceuticals (NASDAQ:NRXP) has agreed with Hungarian Health Officials on a regulatory path for emergency use of aviptadil (Zyesami) in the Central European region, beginning with a compassi...
GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent com...
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Vi...
Relief Therapeutics (OTCQB:RLFTF) announces a series of executive changes. Nermeen Varawalla, MD, PhD, MBA has been appointed to the position of Chief Medical Officer, reporting to Raghuram (Ram) Selvaraju, PhD, MBA, Chairman of Relief. Dr. Varawalla will replace Gilles Della Corte, MD, who i...
Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD Jeremy Meinen promoted to Chief Accounting Officer Marco Marotta promoted to Chief Business Officer GENEVA, SWITZERLAND / ACCESSWIRE / November 30, 2021 / RELIEF THERAPEUTICS Ho...
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent com...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...